Posts

Readmission on the Horizon: How EU funding can boost Br...

In the second edition of Money Moves, we look at how European funding could help...

STAT+: In early trial, drug appears to reduce harmful p...

An early trial of a drug offer hope for people with ATTR-CM, a type of heart dis...

STAT+: Soft, stretchable electronic skin could reconstr...

A Stanford team has built soft, stretchable electronic skin that aims to restore...

STAT+: After new cluster, health officials warn mpox co...

Mpox has “a substantial risk of resurgence” health officials say, warning people...

Tokyo Tech and HPE collaborate to build the next genera...

Tokyo Institute of Technology (Tokyo Tech) Global Scientific Information and Com...

New device gently moves esophagus, making heart ablatio...

A new device invented with the help of an electrophysiologist at The Ohio State ...

Healthcare-focused startup secures $50M from General Ca...

Healthcare startup Hippocratic AI has emerged with $50 million in funding to dev...

Cost of disease-modifying therapies for multiple sclero...

While MS is not a terminal diagnosis, the effect of the disease on the CNS can s...

US FDA accepts Satsuma’s 505(b)(2) NDA for STS101

The NDA was supported by data obtained from the Phase I clinical trial and the P...

Myeloid raises funds to support lead cell therapy progr...

The financing will help to fast-track the development of other in vivo programmi...

Treatment options for Crohn’s disease expand after Rinv...

AbbVie’s blockbuster drug Rinvoq earned its seventh approval to become the first...

Supreme Court backs Sanofi in high-profile cholesterol ...

The justices’ verdict concludes a long legal battle between the companies over p...

Oncology biosimilar case studies: rituximab biosimilars

The first approved biosimilar in the US and EU was Celltrion/Teva Pharmaceutical...

OncoResponse receives CPRIT grant to advance OR502

OR2805 was discovered using the company’s B cells discovery platform.

SiteOne secures funding from NIDA for non-opioid therap...

The grant is a UG3/UH3 phase innovation awards co-operative agreement in two pha...

Alimera Sciences buys US rights to EyePoint’s Yutiq

Yutiq received the US Food and Drug Administration's approval in October 2018.